Schechter M D
Department of Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown 44272, USA.
Pharmacol Biochem Behav. 1998 Jan;59(1):19-25. doi: 10.1016/s0091-3057(97)00309-2.
The benzodiazepine flunitrazepam (Rohypnol) was employed to control differentially discriminative performance in 10 Sprague-Dawley rats on a food-motivated FR10 schedule. The training dose was 2.5 mg/kg, and 20 min was employed between intraperitoneal administration and training; both values were employed in this study, which, in reality, is the first time in the drug discrimination literature for the training of this drug. Dose-response experiments indicated decreasing discriminative performance in concert with decreasing time to reach FR10 lever selection as the dose tested decreased from 2.5 to 0.04 mg/kg. The calculated ED50 for discriminative performance, i.e., lever selection of the drug-correct lever, was 0.076 mg/kg. The relatively few sessions needed to reach discrimination criterion, and the fact that the ED50 value was 1/33 of the training dose, suggests that a lower dose of Rohypnol may be used in the future to train rats in this paradigm. Time course experiments indicate decreasing discriminative performance from 20-240 min postadministration with a calculated half-life of 162.3 min. Administration of 450, 600, and 900 mg/kg ethanol (10% w/v) I.P. produced saline-like discriminative responding, whereas the combination of these doses with the 0.08 mg/kg Rohypnol dose produced increasing discriminative performance with the highest ethanol dose producing 72.2% Rohypnol-appropriate lever selections in a mean time to attain lever selection on the FR10 schedule of 12.8 s. These results suggest that a lower training dose of Rohypnol may allow for testing of a smaller ED50 Rohypnol dose with ethanol to produce a more complete generalization. The ability of flumenazil (Ro 15-1788) to dose dependently block the discrimination of Rohypnol suggests that this benzodiazepine produces its action by its agonistic efficacy at these receptors. The coadministration of Rohypnol and ethanol as a popular drug combination in humans is discussed, and evidence is offered as to their synergistic interactions in rat discrimination.
使用苯二氮䓬类药物氟硝西泮(罗眠乐)对10只斯普拉格 - 道利大鼠在以食物为动机的FR10程序上进行差异辨别性能控制。训练剂量为2.5毫克/千克,腹腔注射与训练之间间隔20分钟;本研究采用了这两个数值,实际上这是药物辨别文献中首次对该药物进行这样的训练。剂量 - 反应实验表明,随着测试剂量从2.5毫克/千克降至0.04毫克/千克,辨别性能下降,同时达到FR10杠杆选择的时间也减少。计算得出的辨别性能的半数有效剂量(ED50),即选择药物正确杠杆的能力,为0.076毫克/千克。达到辨别标准所需的实验次数相对较少,且ED50值为训练剂量的1/33,这表明未来可能使用较低剂量的罗眠乐在此范式中训练大鼠。时程实验表明,给药后20 - 240分钟辨别性能下降,计算得出的半衰期为162.3分钟。腹腔注射450、600和900毫克/千克乙醇(10% w/v)产生类似生理盐水的辨别反应,而这些剂量与0.08毫克/千克罗眠乐剂量联合使用时,辨别性能增强,最高乙醇剂量在FR10程序上平均达到杠杆选择时间为12.8秒时产生72.2%的罗眠乐适宜杠杆选择。这些结果表明,较低的罗眠乐训练剂量可能允许用较低的罗眠乐ED50剂量与乙醇进行测试,以产生更完整的泛化。氟马西尼(Ro 15 - 1788)能够剂量依赖性地阻断罗眠乐的辨别,这表明这种苯二氮䓬类药物通过其在这些受体上的激动剂效力发挥作用。文中讨论了罗眠乐和乙醇在人类中作为常见药物组合的共同使用情况,并提供了它们在大鼠辨别中协同相互作用的证据。